High Number Of Dropouts Spoil Oxytrex Phase III Trial
Shares in Pain Therapeutics Inc. lost nearly 20% of their value on news that a Phase III study of Oxytrex was inadequate due to patient dropouts, meaning another trial is in order. (BioWorld Today)